GAST

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, GAST Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GAST data layer compared with 17 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GAST Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GAST expression acts as an unfavorable survival marker.

LIHC are the cancer types where GAST Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
LIHCDFSMedianAll0.0860.544<.00121view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration